Neurotransmission

Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections

Retrieved on: 
Monday, November 27, 2023
DSMB, Cell death, TDP43, Neurotransmission, News, Inflammation, PD, Thought, Patient, Axonal transport, Data, Safety, Memory, Amyloid, Pharmaceutical industry

The phase II/III study is a randomized, double-blind, placebo-controlled trial investigating the efficacy, safety, and tolerability of buntanetap in patients with mild to moderate AD.

Key Points: 
  • The phase II/III study is a randomized, double-blind, placebo-controlled trial investigating the efficacy, safety, and tolerability of buntanetap in patients with mild to moderate AD.
  • Buntanetap’s mechanism of action, favorable toxicology profile, and oral mode of administration distinguish it as superior to other AD drugs.
  • The efficacy and safety analysis reviewed by the DSMB recommended that Annovis continue the trial as originally designed.
  • This not only proves their support but also underscores their willingness to contribute to advancing this important cause.”

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

Retrieved on: 
Wednesday, December 6, 2023
Alzheimer's disease, Research, Cell biology, Treatment, International Association, Neurotransmission, Learning, Disease, Patient, Journal, Therapy, Biomedical sciences, University, Memory, Dementia, Pharmaceutical industry, Medical device, Medicine, Physiology, Pharmacy, NEW YORK

NEW YORK, Dec. 6, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that its President and Chief Scientific Officer, Daniel Alkon, M.D., will join more than 30 leading neuroscientists and academics as a speaker at IABS Forum-2023, "New Concepts for the Treatment of Neurodegenerative Disorders." The distinguished scientific forum, to be held on December 7-8, 2023 in Irvine, CA, is co-sponsored by the University of Southern California School of Pharmacy and the International Association of Biomedical Sciences (IABS).

Key Points: 
  • The distinguished scientific forum, to be held on December 7-8, 2023 in Irvine, CA, is co-sponsored by the University of Southern California School of Pharmacy and the International Association of Biomedical Sciences (IABS).
  • The forum's keynote address, entitled "Towards a Cell Biology of Alzheimer's Disease," will be delivered by Dr. Thomas Südhof, Nobel Laureate in Physiology or Medicine 2013.
  • Dr. Südhof is known for his groundbreaking research on the mechanisms underlying synaptic transmission, which plays a vital role in learning, memory, and various neurological processes.
  • A research article detailing the results was published earlier this year in the Journal of Alzheimer's Disease.

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023

Retrieved on: 
Friday, November 3, 2023
Research, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, MD Anderson Cancer Center, Neurotransmission, NCI, Food, Cytarabine, Alliance for Clinical Trials in Oncology, Inflammation, Safety, European Medicines Agency, Sickle cell disease, Volunteering, ASH, Pharmacokinetics, Cancer, National Cancer Institute, PIP, NDA, Cladribine, Patient, Food and Drug Administration, AML, D, Pharmaceutical industry, Glycomimetic

GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the third quarter ended September 30, 2023.

Key Points: 
  • GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the third quarter ended September 30, 2023.
  • With the addition of the time-based analysis, the company expects topline results by the end of Q2 2024.
  • Third Quarter 2023 Financial Results:
    Cash position: As of September 30, 2023, GlycoMimetics had cash and cash equivalents of $49.4 million as compared to $47.9 million as of December 31, 2022.
  • A live webcast of the call will be available on the “ Investors ” tab on the GlycoMimetics website.

PANTHERx® Selected by UCB as part of the Limited Specialty Pharmacy Network for RYSTIGGO®(rozanolixizumab-noli), for the Treatment of Generalized Myasthenia Gravis (gMG)

Retrieved on: 
Wednesday, August 2, 2023
Extremities, Neurotransmission, MuSK protein, GMG, Weakness, Antibody, Full, Muscle weakness, UCB, Neuromuscular junction, Patient, Muscle fatigue, Acetylcholine receptor, FDA, Autoantibody, Disease, Pharmaceutical industry

Generalized Myasthenia Gravis is a rare, chronic autoimmune disease that results from pathogenic autoantibodies impairing synaptic transmission at the neuromuscular junction.

Key Points: 
  • Generalized Myasthenia Gravis is a rare, chronic autoimmune disease that results from pathogenic autoantibodies impairing synaptic transmission at the neuromuscular junction.
  • 2-3 These autoantibodies primarily consist of AChR or MuSK antibodies.
  • 4 The resultant damage manifests as muscle fatigue and weakness.
  • We are happy to be able to help some individuals living with Generalized Myasthenia Gravis with the distribution of RYSTIGGO," said Rob Snyder, CEO of PANTHERx® Rare.

GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023

Retrieved on: 
Wednesday, August 2, 2023
Biotechnology, Health, Oncology, Clinical Trials, Dana–Farber Cancer Institute, Neurotransmission, Clinical trial, Boston, Age, Research, FLA, AML, Data, Patient, Cancer, Sickle cell disease, Hospital, FDA, NCI, MPH, Safety, Inflammation, D, Pharmaceutical industry, MD, Glycomimetic

GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the second quarter ended June 30, 2023.

Key Points: 
  • GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the second quarter ended June 30, 2023.
  • With the addition of a time-based analysis, the company now expects to report topline results by the end of Q2 2024.
  • In May 2023, FDA agreed to the initial Pediatric Study Plan (iPSP) submitted by GlycoMimetics.
  • Second Quarter 2023 Financial Results:
    Cash position: As of June 30, 2023, GlycoMimetics had cash and cash equivalents of $58.0 million as compared to $47.9 million as of December 31, 2022.

InSilicoTrials and Axoltis Pharma Collaborate to Advance Therapeutic Solutions for Neurological Disorders

Retrieved on: 
Thursday, July 27, 2023
Neuroprotection, Partnership, Neurotransmission, Drug development, Neurogenesis, Disease, University, DSM-IV codes, SCO-spondin, ALS, Research, Multimedia, CNS, Central nervous system, Multiple sclerosis, MS, HIV disease progression rates, CM, Patient, Amyotrophy, Central nervous system disease, Apoptosis, Parkinson's disease, Artificial intelligence, AI, Ecosystem, Safety, Fine chemical, Pharmaceutical industry, Medical device

Mechanistic CNS models are designed to simulate the physiological and pathological aspects of CNS disorders, providing insights into the disease mechanisms and potential therapeutic interventions.

Key Points: 
  • Mechanistic CNS models are designed to simulate the physiological and pathological aspects of CNS disorders, providing insights into the disease mechanisms and potential therapeutic interventions.
  • Given that Axoltis drug candidate NX210c targets these features, the collaboration with InSilicoTrials holds great promise for supporting CNS functions in a wide range of neurological and neurodegenerative conditions.
  • "We are thrilled to collaborate with Axoltis in our shared mission to advance therapeutic solutions for neurological disorders," said Luca Emili, CEO of InSilicoTrials.
  • Axoltis Pharma is a French biopharmaceutical company dedicated to developing a first-in-class disease-modifying drug to treat patients with neurodegenerative or traumatic neurological disorders with high unmet medical needs.

InSilicoTrials and Axoltis Pharma Collaborate to Advance Therapeutic Solutions for Neurological Disorders

Retrieved on: 
Thursday, July 27, 2023
Neuroprotection, Partnership, Neurotransmission, Drug development, Neurogenesis, Disease, University, DSM-IV codes, SCO-spondin, ALS, Research, CNS, Central nervous system, Multiple sclerosis, MS, HIV disease progression rates, CM, Patient, Amyotrophy, Central nervous system disease, Apoptosis, Parkinson's disease, Artificial intelligence, AI, Ecosystem, Safety, Fine chemical, Medical device

Mechanistic CNS models are designed to simulate the physiological and pathological aspects of CNS disorders, providing insights into the disease mechanisms and potential therapeutic interventions.

Key Points: 
  • Mechanistic CNS models are designed to simulate the physiological and pathological aspects of CNS disorders, providing insights into the disease mechanisms and potential therapeutic interventions.
  • Given that Axoltis drug candidate NX210c targets these features, the collaboration with InSilicoTrials holds great promise for supporting CNS functions in a wide range of neurological and neurodegenerative conditions.
  • "We are thrilled to collaborate with Axoltis in our shared mission to advance therapeutic solutions for neurological disorders," said Luca Emili, CEO of InSilicoTrials.
  • Axoltis Pharma is a French biopharmaceutical company dedicated to developing a first-in-class disease-modifying drug to treat patients with neurodegenerative or traumatic neurological disorders with high unmet medical needs.

UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis

Retrieved on: 
Tuesday, June 27, 2023
GTA MyCar, Neurotransmission, University, MuSK protein, Lancet Neurology, GMG, Pathology, Fc receptor, Acetylcholine, Disease management, Immunoglobulin G, There, Information, U.S. FDA, UCB, Protein, Patient, University of Toronto, Division, Brussels Stock Exchange, Autoimmune disease, NMJ, University Health Network, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, The Lancet, Food, Safety, Disease, Pharmaceutical industry, Vaccine, Neurology

"There is a significant need for new, innovative treatment options to reduce the day-to-day burden of gMG.

Key Points: 
  • "There is a significant need for new, innovative treatment options to reduce the day-to-day burden of gMG.
  • RYSTIGGO ® is a new treatment option, targeting one of the mechanisms of disease to provide symptom improvement in patient-and physician reported outcomes at day 43."
  • The approval of RYSTIGGO® means doctors have an additional approved treatment option for their gMG patients who have not yet found a treatment that meets their needs."
  • RYSTIGGO® is also currently under review by the European Medicines Agency (EMA) and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for the treatment of adults with gMG.

EQS-News: Abivax reports 2022 financial results and operations update

Retrieved on: 
Wednesday, April 19, 2023
Operating cost, CD, US Foods, Marketing, United European Gastroenterology, G&A, Malignancy, Congress, COVID-19, Investment, Patient, Ageing, ITT, ARD, HCC, Rheumatoid arthritis, Maintenance, Sofinnova, Neurotransmission, Clinical and Translational Gastroenterology, Methotrexate, De novo, EMA, Cancer, CTG, EULAR, Mall of America, FDA, Natural killer T cell, Safety, European Medicines Agency, Volunteering, Inflammatory Bowel Diseases, PIP, UEG, Ulcerative colitis, Publication, Blood, MTX, Nivolumab, Partnership, RA, ACR20, IBD, Bank statement, ECCO, Bristol Myers Squibb, CCO, Fungal infection, ASCO, EUR, Scripps, Food, Pharmaceutical industry, Management, Abivax, Rheumatology, UC, Gastroenterology

The ABTECT program was initiated in the first half of 2022 and the first patient in the United States was enrolled on October 11, 2022.

Key Points: 
  • The ABTECT program was initiated in the first half of 2022 and the first patient in the United States was enrolled on October 11, 2022.
  • Abivax recently reported the results of its Phase 2b maintenance trial of obefazimod in UC after two years of continued once-daily treatment with 50mg obefazimod.
  • In March 2022, Abivax announced its Phase 2a maintenance trial results of obefazimod in RA.
  • In January 2022, Abivax presented the results of the dose escalation phase of its Phase 1/2 clinical trial in HCC at the ASCO GI Cancers Symposium.

Annovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental Illnesses

Retrieved on: 
Wednesday, February 1, 2023
Axonal transport, Patent, Huntington's disease, Brain, Medicine, DSM-IV codes, Human, ALS, PD, Protein, Neurotoxicity, Traumatic brain injury, Gian Maria Annovi, NYSE, Attention deficit hyperactivity disorder predominantly inattentive, ADHD, Schizophrenia, Inflammation, Bipolar disorder, Alzheimer's disease, Health, Spectrum, Stroke, Mental, CTE, AD, Chronic traumatic encephalopathy, Neurotransmission, Parkinson's disease, Prion, Communication, FTD, Frontotemporal dementia, Pharmaceutical industry, Dietary supplement, Vaccine, Lancet, Amyloid beta

In certain embodiments, the invention covers methods and pharmaceutical compositions of a large group of buntanetap analogs for preventing, treating, inhibiting, reducing, slowing, or delaying mental illnesses in humans.

Key Points: 
  • In certain embodiments, the invention covers methods and pharmaceutical compositions of a large group of buntanetap analogs for preventing, treating, inhibiting, reducing, slowing, or delaying mental illnesses in humans.
  • In certain embodiments, the mental illness is autism, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, or schizophrenia.
  • These neurotoxic proteins cause impairment in axonal transmission and inflammation, similar to what is seen in neurodegenerative diseases.
  • The Company has been issued patents covering a wide range of neurodegenerative diseases, and this patent, if granted, would represent a significant expansion of Annovis' intellectual property portfolio.